small biotech is always a risky game, but at least FAK...

small biotech is always a risky game, but at least FAK inhibitors have already been shown elsewhere to be efficacious in clinical trials:

FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials
https://www.tandfonline.com/doi/abs/10.1080/13543784.2020.1740680?journalCode=ieid20

"The FAK inhibitors examined in clinical trials thus far have been shown to have manageable toxicity profiles and have demonstrated cytostatic effects as single agents, extending progression-free survival without producing a clinical or radiographic response. Trials are currently underway to strengthen the efficacy of treatment by combining FAK inhibitors with cytotoxic chemotherapy, targeted therapy, or immunotherapy. "

and with the current atx market cap, seems almost nothing is priced in here